Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Forbion
Deal Size : $112.0 million
Deal Type : Series B Financing
Details : The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound NOE-101 (basimglurant), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in TN and sei...
Product Name : NOE-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 03, 2023
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Forbion
Deal Size : $112.0 million
Deal Type : Series B Financing
Lead Product(s) : Dipraglurant
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Following oral administration, ADX48621 (dipraglurant) was rapidly absorbed and readily crossed the blood-brain barrier. In vivo, dipraglurant administration was found to dose-dependently impact the various NMS disease models.
Product Name : ADX48621
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : Dipraglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Noema Pharma Receives FDA Fast Track Designation for Basimglurant (NOE-101) in Trigeminal Neuralgia
Details : Basimglurant (NOE-101) is a highly selective, potent, and cell-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) for the treatment of trigeminal neuralgia (TN).
Product Name : NOE-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2022
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dipraglurant
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Armistice Master Fund
Deal Size : $4.2 million
Deal Type : Financing
Addex Completes $4.2 Million Equity Financing
Details : Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).
Product Name : ADX48621
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 26, 2022
Lead Product(s) : Dipraglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Armistice Master Fund
Deal Size : $4.2 million
Deal Type : Financing
Lead Product(s) : Dipraglurant
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Armistice Master Fund
Deal Size : $4.2 million
Deal Type : Financing
Addex Raises $4.2 Million in Equity Financing
Details : Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).
Product Name : ADX48621
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 22, 2022
Lead Product(s) : Dipraglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Armistice Master Fund
Deal Size : $4.2 million
Deal Type : Financing
Lead Product(s) : Dipraglurant
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADX48621 (Dipraglurant (Immediate Release), as a novel orally available mGlu5 NAM, for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).
Product Name : ADX48621
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2022
Lead Product(s) : Dipraglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NOE-101 (basimglurant), a highly selective, potent, and cell-penetrant negative allosteric modulator of mGlu5 receptors for the management of pain associated with TN.
Product Name : NOE-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2022
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gantenerumab
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche experimental drug flops in early Alzheimer’s
Details : Gantenerumab, did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer’s disease.
Product Name : RG1450
Product Type : Antibody
Upfront Cash : Inapplicable
October 02, 2020
Lead Product(s) : Gantenerumab
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable